1. Effect of the thrombin receptor antagonist (PAR‐1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo‐ and positive‐controlled, parallel group trial. Issue 1 (25th September 2013) Authors: Kosoglou, Teddy; Hunt, Thomas L.; Xuan, Fengjuan; Kumar, Bharath; Statkevich, Paul; Hanson, Mary E.; Cutler, David L. Journal: Clinical pharmacology in drug development Issue: Volume 3:Issue 1(2014:Jan./Feb.) Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evaluation of Eluxadoline Effect on Cardiac Repolarization. Issue 7 (16th April 2018) Authors: Bonifacio, Laura; Hunt, Thomas L.; McIntyre, Gail; Dove, Leonard S.; Covington, Paul S. Journal: Clinical pharmacology in drug development Issue: Volume 7:Issue 7(2018) Page Start: 727 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double‐blind, placebo‐, and active‐controlled thorough QT study. (6th May 2014) Authors: Zuo, Peiying; Haberer, Lynda J.; Fang, Lei; Hunt, Thomas L.; Ridgway, Derry; Russo, Mark W. Journal: Journal of clinical pharmacology Issue: Volume 54:Number 11(2014:Nov.) Page Start: 1221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗